Cyclic Peptides Patents (Class 530/317)
  • Publication number: 20140051828
    Abstract: The present invention relates to a method for preparing a peptide having a stable, internally constrained alpha-helical, beta-sheet/beta-turn, 310-helical, or pi-helical region and a method of stabilizing an alpha-helical, beta-sheet/beta-turn, 310-helical, or pi-helical region within a peptide structure. The resulting peptides and methods of using them are also disclosed.
    Type: Application
    Filed: April 23, 2013
    Publication date: February 20, 2014
    Inventor: New York University
  • Patent number: 8653235
    Abstract: Provided are a cyclic peptide compound or a pharmacologically acceptable salt thereof capable of inhibiting parakeratosis of skin, and a method for producing the same.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: February 18, 2014
    Assignee: Kwansei Gakuin Educational Foundation
    Inventors: Yohei Hirai, Yoji Okugawa
  • Publication number: 20140046021
    Abstract: The molecular structures of metal-salen complexes which exerts pharmacological effects are clarified and the metal-salen complexes having such molecular structures and their derivatives are provided. A metal-salen complex compound is characterized in that a metal atom part in each of multiple molecules of the metal-salen complex or its derivative is multimerized via water.
    Type: Application
    Filed: January 19, 2012
    Publication date: February 13, 2014
    Applicants: IHI CORPORATION
    Inventors: Yoshihiro Ishikawa, Haruki Eguchi
  • Publication number: 20140044754
    Abstract: The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders.
    Type: Application
    Filed: February 26, 2013
    Publication date: February 13, 2014
    Inventors: William D. Carlson, Peter C. Keck, Michael Sworin, Dattatreyamurty Bosukonda
  • Patent number: 8648169
    Abstract: The present invention relates to methods of treating or preventing retinal ganglion cell (RGC) death and/or glaucoma using modulators of neurotrophic receptors that comprise ?-turn peptidomimetic cyclic compounds or derivatives thereof. The neurotrophic receptor modulators can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat or prevent ocular hypertension, RGC death and/or glaucoma.
    Type: Grant
    Filed: December 5, 2007
    Date of Patent: February 11, 2014
    Assignee: The Royal Institution for the Advancement of Learning/McGill University
    Inventor: H. Uri Saragovi
  • Publication number: 20140038886
    Abstract: The present invention relates to hydrophobic modified peptides for the specific delivery of compounds to the liver, preferably to hepatocytes, in vitro as well as in vivo. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified peptide(s) and the compound(s) to be specifically delivered to the liver. The present invention furthermore relates to the use of the inventive hydrophobic modified peptides as well as to a method for the prevention and/or treatment of liver diseases or disorders.
    Type: Application
    Filed: February 10, 2012
    Publication date: February 6, 2014
    Applicant: RUPRECHT-KARIS-UNVERSITAT HEIDELBERG
    Inventors: Walter Mier, Stephan Urban, Stefan Mehrle, Uwe Haberkorn
  • Patent number: 8642558
    Abstract: Methods, systems and compositions comprising novel peptidomimetics are disclosed that can be used to inhibit calpain and, more specifically, to treat tissue damage caused by pathologic activation of calpains.
    Type: Grant
    Filed: September 21, 2009
    Date of Patent: February 4, 2014
    Assignee: Henry Ford Health Systems
    Inventors: John Anagli, Donald Seyfried
  • Patent number: 8636977
    Abstract: The present invention relates to a novel class of diagnostically or therapeutically effective compounds comprising novel aza-bicycloalkane based cyclic peptides, acting as a targeting moiety towards integrin receptors.
    Type: Grant
    Filed: March 3, 2006
    Date of Patent: January 28, 2014
    Assignee: Bracco Imaging S.p.A.
    Inventors: Luciano Lattuada, Pierfrancesco Morosini, Fulvio Uggeri, Silvio Aime, Enzo Terreno, Daniela Delli Castelli, Carlo Scolastico, Leonardo Manzoni, Daniela Arosio
  • Patent number: 8637451
    Abstract: A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: January 28, 2014
    Assignee: Synergy Pharmaceuticals Inc.
    Inventors: Kunwar Shailubhai, Gregory Nikiforovich, Gary S. Jacob
  • Publication number: 20140024605
    Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.
    Type: Application
    Filed: April 5, 2013
    Publication date: January 23, 2014
    Applicant: SYNERGY PHARMACEUTICALS INC.
    Inventors: Kunwar Shailubhai, Gary S. Jacob
  • Patent number: 8632781
    Abstract: The present invention relates to peptides derived from the proinflammatory cytokines, interleukin-1? (IL1?) and tumor necrosis factor ? (TNF?), and their use in human or veterinary therapy, such as to generally treat diseases linked to the overproduction of IL1? or TNF? as well as acute or chronic inflammatory diseases, rheumatoid arthritis, septic shock, autoimmune diabetes, graft rejection in the host, etc.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: January 21, 2014
    Assignee: Vaxconsulting
    Inventors: Jean-Francois Zagury, Marie-Christophe Boissier, Natacha Bessis
  • Patent number: 8629241
    Abstract: Disclosed are short chain peptides that are constrained to adopt an alpha helicial conformation and their use as alpha helical scaffolds for directing amino acid side chains into positions analogous to those found in longer chain alpha helical peptides. Also disclosed is the use of these peptides for attaching peptidic or non-peptidic appendages in order to mimic side chains of longer alpha helical peptides. The peptides find use in mimicking naturally occurring peptides or proteins or in preparing new materials.
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: January 14, 2014
    Assignee: The University of Queensland
    Inventors: David P. Fairlie, Nicholas E. Shepherd
  • Patent number: 8629112
    Abstract: Specific template-fixed ?-hairpin peptidomimetics of the general formula (I) wherein the single elements T or P are ?-amino acid residues connected from the carbonyl (C?O) point of attachment to the nitrogen (N) of the next element in clockwise direction and wherein said elements, depending on their positions in the chain, are defined in the description and the claims have the property to act on the receptor CXCR7. Thus, these ?-hairpin peptidomimetics can be useful in the treatment or prevention of diseases or conditions in the area of dermatological disorders, metabolic diseases, inflammatory diseases, fibrotic diseases, infectious diseases, neurological diseases, cardiovascular diseases, respiratory diseases, gastro-intestinal tract disorders, urological diseases, ophthalmic diseases, stomatological diseases, haematological diseases and cancer; or the mobilization of stem cells.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: January 14, 2014
    Inventors: Frank Otto Gombert, Alexander Lederer, Daniel Obrecht, Barbara Romagnoli, Christian Bisang, Christian Ludin
  • Patent number: 8628781
    Abstract: Provided herein are polypeptides comprising or consisting essentially of a QSYDNTLSGSYVF (SEQ ID NO:1) or LSADSSGSYLYVF (SEQ ID NO:2) amino acid sequence. Also provided herein are methods of treating or preventing cast nephropathy in a subject. The methods comprise identifying a subject with or at risk of developing cast nephropathy and administering to the subject any of the polypeptides disclosed herein.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: January 14, 2014
    Assignees: The UAB Research Foundation, The United States of America, as Represented by the Department of Veterans Affairs
    Inventor: Paul W. Sanders
  • Publication number: 20140005126
    Abstract: A naive WW domain peptide library derived from a WW domain peptide sequence which has been diversified by changing the amino acid sequence at one or more positions is provided. The naive WW domain peptide library may be derived from a GroupIV WW domain peptide. Methods for making the naive WW domain peptide library and methods for selected a modified WW domain peptide that binds a target ligand using the naive WW domain peptide library are also provided. Also disclosed are modified WW domain peptides that bind desired target ligands, pharmaceutical compositions comprising such peptides, and uses for such peptides. The modified WW domain peptides have altered, improved or different, target ligand binding characteristics to those of the unmodified WW domain peptides from which they are derived.
    Type: Application
    Filed: August 8, 2011
    Publication date: January 2, 2014
    Applicant: ISOGENICA LTD
    Inventors: Chris Ullman, Agnes Jaulent, Seema Patel, Pascale Mathonet
  • Publication number: 20140004041
    Abstract: The present invention relates to technetium imaging agents comprising radiolabeled c-Met binding peptides suitable for SPECT or PET imaging in vivo. The c-Met binding peptides are labelled via chelator conjugates. Also disclosed are pharmaceutical compositions, methods of preparation of the agents and compositions, plus methods of in vivo imaging using the compositions, especially for use in the diagnosis of cancer.
    Type: Application
    Filed: March 2, 2012
    Publication date: January 2, 2014
    Applicant: GE HEALTHCARE LIMITED
    Inventors: Peter Brian Iveson, Bard Indrevoll, Ben Newton, Rajiv Bhalla, Edvin Wilhelm Johannesen
  • Publication number: 20140005104
    Abstract: The present invention discloses the structure, preparation methods and uses of a series of novel polyheterocyclic based compounds (Ia-Ib and IIa-IIb) that are highly effective for inhibiting hepatitis C virus (HCV): where the structural variables are defined herein. The present invention is also provides a method of treating HCV infection by the polyheterocyclic based HCV inhibitory compounds, compositions and therapeutic methods.
    Type: Application
    Filed: September 3, 2013
    Publication date: January 2, 2014
    Applicant: AB Pharma Ltd.
    Inventor: Zheng-Yun James ZHAN
  • Patent number: 8618065
    Abstract: A cyclosporin derivative of general Formula (I) or a pharmaceutically compatible salt thereof, which have a pharmaceutical effectiveness, for example in the case of chronic inflammatory diseases. The cyclosporin derivatives are preferably free from a peptide section capable of passing through the membrane of a biological cell.
    Type: Grant
    Filed: February 15, 2012
    Date of Patent: December 31, 2013
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften E.V.
    Inventors: Gunter Fischer, Miroslav Malesevic, Frank Erdmann, Jan Kühling, Michael Bukrinsky, Stephanie Constant
  • Patent number: 8618055
    Abstract: Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration.
    Type: Grant
    Filed: January 27, 2011
    Date of Patent: December 31, 2013
    Assignee: Children's Medical Center Corporation
    Inventors: Avner Adini, Robert D'Amato
  • Publication number: 20130343989
    Abstract: Disclosed are compositions and methods useful for targeting tissue undergoing angiogenesis or to cells or tissue expressing ?v integrins. The compositions and methods are based on peptide sequences that selectively bind to and home to tissue undergoing angiogenesis or to cells or tissue expressing ?v integrins in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to tissue experiencing angiogenesis or to cells or tissue expressing ?v integrins.
    Type: Application
    Filed: January 30, 2013
    Publication date: December 26, 2013
    Applicant: Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Kazuki Sugahara, Tambet Teesalu
  • Publication number: 20130344592
    Abstract: Factor H-binding peptides that binds to a region of factor H that does not impede the complement-inhibitory activity of factor H are disclosed. When immobilized onto the surface of a biomaterial, these peptides recruit factor H, resulting in a substantial inhibition of biomaterial-induced complement activation in a biological substance exposed to the biomaterial.
    Type: Application
    Filed: December 19, 2011
    Publication date: December 26, 2013
    Inventor: John D. Lambris
  • Publication number: 20130344029
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.
    Type: Application
    Filed: June 7, 2013
    Publication date: December 26, 2013
    Inventors: Caroline Aciro, Victoria Alexandra Steadman, Simon Neil Pettit, Karine G. Poullennac, Linos Lazarides, David Kenneth Dean, Neil Andrew Dunbar, Adrian John Highton, Andrew John Keats, Dustin Scott Siegel, Kapil Kumar Karki, Adam James Schrier, Petr Jansa, Richard Mackman
  • Publication number: 20130344030
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.
    Type: Application
    Filed: June 7, 2013
    Publication date: December 26, 2013
    Inventors: Victoria Alexandra Steadman, Karine G. Poullennec, Linos Lazarides, Caroline Aciro, David Kenneth Dean, Andrew John Keats, Dustin Scott Siegel, Adam James Schrier, Richard Mackman, Petr Jansa
  • Patent number: 8614193
    Abstract: The subject application pertains to a compound of structure IX or X: or a pharmaceutically acceptable salt thereof, wherein: X is —C(?O)N(R10)— or —CH(OPr3) —; R7, R9 and R10 are the same or different and represent hydrogen or an amino acid side chain moiety from either a natural or an unnatural amino acid; Pr1 and Pr2 are the same or different and represent hydrogen or a thiol protecting group; Pr3 is hydrogen or an alcohol protecting group; R1, R2, R5 and R6 are the same or different and represent hydrogen or an amino acid side chain moiety from either a natural or an unnatural amino acid, or R1 and R2 and/or R5 and R6, taken together with the carbon atom to which they are attached, form a spirocyclic moiety, with the proviso that: each of R1 and R2 is not hydrogen, or each of R5 and R6 is not hydrogen.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: December 24, 2013
    Assignee: Karus Therapeutics Limited
    Inventors: Stephen Joseph Shuttleworth, Franck Alexandre Silva, Cyrille Davy Tomassi, Alexander Richard Liam Cecil, Thomas James Hill
  • Patent number: 8614289
    Abstract: The invention relates to a method or process for the chemical manufacture of depsipeptides of the formula I, wherein the symbols have the meaning defined in the description, to new intermediates and their manufacture, as well as related invention embodiments.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: December 24, 2013
    Assignee: Novartis AG
    Inventors: Murat Acemoglu, Heribert Hellstern, Felix Kollmer, John Lopez, Robert Schreiber, Christian Sprecher, Hans Stettler
  • Publication number: 20130338075
    Abstract: The present invention generally relates to methods and compositions for preventing or treating axonal and/or neuronal degeneration in a subject by administering a composition comprising a peptide that comprises the amino acid sequence Arginine-Glycine-Aspartate (RGD).
    Type: Application
    Filed: June 13, 2013
    Publication date: December 19, 2013
    Inventor: Thien Nguyen
  • Publication number: 20130338023
    Abstract: A method for measuring the proliferation status of a cell present in a biological sample, comprising the step of measuring in the said cell the loss of BACH2 by Fluorescence after In Situ Hybridization (FISH) analysis and mRNA quantification or by Comparative Genomic Hybridization (CGH) and corresponding kit and applications.
    Type: Application
    Filed: October 12, 2011
    Publication date: December 19, 2013
    Applicant: UNIVERSITE LIBRE DE BRUXELLES
    Inventors: Karen Willard-Gallo, Catherine Sibille
  • Patent number: 8609809
    Abstract: Novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production are provided.
    Type: Grant
    Filed: January 19, 2010
    Date of Patent: December 17, 2013
    Assignee: Aileron Thraputics, Inc.
    Inventor: Huw M. Nash
  • Patent number: 8603756
    Abstract: The present invention provides for the identification of an antigen surrogate to the native antigens for the autoimmune disease pemphigus vulgaris. Ligands are discovered using large random peptoid or cyclic peptoid libraries that are screened against known antibodies to autoimmune diseases. The ligands may be useful as drugs in the treatment of such diseases and can also be used in combination with the concomitant removal of T-cells associated with autoimmune disorders.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: December 10, 2013
    Assignee: OPKO Pharmaceuticals, LLC
    Inventors: Phillip Frost, Thomas Kodadek
  • Patent number: 8603436
    Abstract: Disclosed are Drug Delivery Molecules (DDMs) which both facilitate functional imaging, as by PET, MRI or SPECT, and create a biological effect and methods of their use. These DDMs which are variously designed to target specific receptors, internalized and then function biologically, as for purposes of cell destruction or therapy.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: December 10, 2013
    Inventor: Gerhart Graupner
  • Patent number: 8604164
    Abstract: The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of Streptomyces roseosporus. The invention also discloses high pressure liquid chromatography methods for analysis of daptomycin purity. The invention also discloses lipopeptide micelles and methods of making the micelles. The invention also discloses methods of using lipopeptide micelles for purifying lipopeptide antibiotics, such as daptomycin. The invention also discloses using lipopeptide micelles therapeutically.
    Type: Grant
    Filed: February 16, 2012
    Date of Patent: December 10, 2013
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: Thomas J. Kelleher, Jan-Ji Lai, Joseph P. DeCourcey, Paul D. Lynch, Maurizio Zenoni, Auro R. Tagliani
  • Patent number: 8603435
    Abstract: The present invention is directed to novel non-invasive diagnostic tools/compounds comprising a cyclic peptide wherein the compound binds to a MSH receptor to image and treat cancers, especially, melanoma, including metastatic melanoma in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probes are capable of detecting cancerous melanoma cells, as well as their metastatic spread in tissues. The present invention represents a step forward in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention are also useful to initiate therapy for melanoma as well as monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma.
    Type: Grant
    Filed: January 12, 2009
    Date of Patent: December 10, 2013
    Assignee: STC.UNM
    Inventors: Yubin Miao, Haixun Guo
  • Patent number: 8598313
    Abstract: In alternative embodiments, the invention provides apratoxin F and apratoxin G compounds, which include apratoxin F and apratoxin G stereoisomers, derivatives and analogs compositions and methods. In alternative embodiments, the invention provides pharmaceutical compositions and formulations comprising apratoxin F (compound 6 of FIG. 1) and apratoxin G (compound 7 of FIG. 1) and their stereoisomers, derivatives and analogs. In alternative embodiments, pharmaceutical compositions and formulations of the invention are administered in an amount sufficient to treat, prevent and/or ameliorate a disease or condition that can be ameliorated by decreasing or inhibiting cell growth, e.g., pathological, uncontrolled or unwanted cell growth, e.g., a cancer or a metastases, or any disease or condition (e.g., allergy) or infection having a hyperproliferative cell growth component.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: December 3, 2013
    Assignee: The Regents of the University of California
    Inventors: William H. Gerwick, Kevin Tidgewell, Frederick A. Valeriote
  • Patent number: 8598316
    Abstract: The present invention provides a conjugate that contains a therapeutic moiety linked to a homing peptide or peptidomimetic which selectively homes to vasculature of pre-malignant dysplastic skin and which includes the amino acid sequence SRPRR (SEQ ID NO: 1) or a conservative variant or peptidomimetic thereof. The present invention further provides a conjugate containing a therapeutic moiety linked to a homing peptide or peptidomimetic which selectively homes to vasculature of malignant skin and which includes the amino acid sequence CGKRK (SEQ ID NO: 6) or the amino acid sequence CDTRL (SEQ ID NO: 7), or a conservative variant or peptidomimetic of one of these sequences.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: December 3, 2013
    Assignees: Sanford-Burnham Medical Research Institute, The Regents of the University of California
    Inventors: Douglas Hanahan, Erkki Ruoslahti
  • Publication number: 20130317195
    Abstract: The present invention provides cyclic peptides comprising a dimer of peptides, each peptide comprising a sequence corresponding to the HER2 splice variant HER2Delta16, wherein the cyclic peptide is cyclized via a disulfide bond between the peptides and via an amino acid linking the peptides. The invention also provides methods of making antibodies that specifically bind to HER2Delta16 homodimers using said cyclic peptides.
    Type: Application
    Filed: May 23, 2013
    Publication date: November 28, 2013
    Inventor: Nicholas Chi-Kwan Ling
  • Publication number: 20130316961
    Abstract: The invention relates to the use of cystamine, cysteamine, or a salt thereof, or of calcineurin inhibitors for treating a MeCP2-associated disorder such as Rett syndrome.
    Type: Application
    Filed: October 24, 2011
    Publication date: November 28, 2013
    Applicants: UNIVERSITÉ D'AIX-MARSEILLE, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (Institut National de la Santé et de la Recherche Médicale)
    Inventors: Jean-Christophe Roux, Laurent Villard, Frédéric Saudou
  • Patent number: 8591878
    Abstract: A class of macrocyclic compounds of formula (I), wherein R1, R3, R4, Ra, Rb, A, B, Z, M, W and n are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: November 26, 2013
    Assignees: Merck Sharp & Dohme Corp., Istituto di Ricerche di Biologia Molecolare P. Angeletti Spa
    Inventors: John A. McCauley, Nigel J. Liverton, Steven Harper, Charles J. McIntyre, Michael T. Rudd
  • Patent number: 8592378
    Abstract: The present invention relates to a new compound useful as a modulator of melanocortin receptors. In particular, the present invention relates to a compound WS727713, a process for production of the compound by culturing, in a culture medium, a WS727713-producing strain belonging to Pseudonocardia and recovering the compound from a culture broth, a pharmaceutical composition containing the compound, and uses of the compound.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: November 26, 2013
    Assignee: Telsar Pharma Inc.
    Inventors: Takanao Otsuka, Hirotsugu Ueda, Keiko Fujie, Hideyuki Muramatsu, Michizane Hashimoto, Shigehiro Takase
  • Publication number: 20130310328
    Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.
    Type: Application
    Filed: July 31, 2013
    Publication date: November 21, 2013
    Inventor: Kunwar Shailubhai
  • Patent number: 8586545
    Abstract: The instant invention relates to novel solid materials of {[(2S,5R,8S,11S)-5-Benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid}, methods for producing them, and the use of said solid materials in pharmaceuticals.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: November 19, 2013
    Assignee: Merck Patent GmbH
    Inventors: Alfred Joncyk, Clemens Kuehn, Kerstin Seemann, Christoph Saal, Gerald Scholz, Soenke Petersen, Harald Untenecker, Michael Lange
  • Patent number: 8586744
    Abstract: The invention is related to a method of treating disorders associated with hepatitis C by administering to an individual a pharmaceutical composition which comprises a therapeutically effective amount of an anti-viral phosphinate compound.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: November 19, 2013
    Assignee: Gilead Sciences, Inc.
    Inventors: Anthony Casarez, Kleem Chaudhary, Aesop Cho, Michael Clarke, Edward Doerffler, Maria Fardis, Choung U. Kim, Hyungjung Pyun, Xiaoning C. Sheng, Jianying Wang
  • Patent number: 8580920
    Abstract: The present invention relates to novel peptides and to topical and food compositions comprising them. The novel peptides have applications in skin lightening and immunomodulation when applied topically and to immunomodulation and modulation of body mass when consumed in food compositions.
    Type: Grant
    Filed: November 23, 2010
    Date of Patent: November 12, 2013
    Assignee: Conopco, Inc.
    Inventors: Ganesh Chandramowli, Babu Rakesh Kumar Bandi
  • Patent number: 8580746
    Abstract: Cyclic constructs which bind to a natriuretic peptide receptor and include a plurality of amino acid residues, at least one amino acid surrogate of formula I: where R, R?, Q, Y, W, Z, J, x and n are as defined in the specification, and a cyclic linkage including one or two amide bonds, pharmaceutical compositions including such cyclic constructs, and methods of treating congestive heart failure or other conditions, syndromes or diseases for which induction of anti-hypertensive, cardiovascular, renal or endocrine effects are desired.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: November 12, 2013
    Assignee: Palatin Technologies, Inc.
    Inventors: Shubh D. Sharma, Margarita Bastos, Wei Yang
  • Patent number: 8580747
    Abstract: Cyclic constructs with an N-terminus and a C-terminus which bind to a natriuretic peptide receptor and include a plurality of amino acid residues, at least one amino acid surrogate of formula I: where R, R?, Q, Y, W, Z, J, x and n are as defined in the specification, and optionally at least one prosthetic group, pharmaceutical compositions including such cyclic constructs, and methods of treating congestive heart failure or other conditions, syndromes or diseases for which induction of anti-hypertensive, cardiovascular, renal or endocrine effects are desired.
    Type: Grant
    Filed: November 19, 2009
    Date of Patent: November 12, 2013
    Assignee: Palatin Technologies, Inc.
    Inventors: Shubh D. Sharma, Margarita Bastos, Wei Yang, Hui-Zhi Cai
  • Publication number: 20130296529
    Abstract: A method for purifying a cyclic lipopepteide or a salt thereof is provided. The method comprises the steps: (1) extracting a fermentation broth containing a compound of formula I or a salt thereof, to obtain an extract 1 after filtration or centrifugation; (2) diluting or concentrating the extract 1 under vacuum to decrease the content of the organic solvent, to obtain an extract 2; (3) loading the extract 2 onto a macroporous absorption resin; (4) washing the macroporpous adsorption resin with water, an organic solvent, or a mixture of water and an organic solvent as a washing solution; and (5) eluting the compound of formula I off from the macroporous adsorption resin with water, an organic solvent, or a mixture of water and an organic solvent as a washing solution as an eluant.
    Type: Application
    Filed: September 27, 2011
    Publication date: November 7, 2013
    Applicant: Shanghai Techwell Biopharmaceutical Co., Ltd.
    Inventors: Zhaoli Zhang, Shidong Liu, Zhonghao Zhuo, Xiaoming Ji
  • Publication number: 20130296256
    Abstract: Melanocortin receptor-specific cyclic peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification, compositions and formulations including the peptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Application
    Filed: June 5, 2013
    Publication date: November 7, 2013
    Applicant: PALATIN TECHNOLOGIES, INC.
    Inventors: Wei Yang, Yi-Qun Shi
  • Publication number: 20130296229
    Abstract: Disclosed are a caspofungin analog and applications thereof. Said caspofungin analog is a compound having a structure as indicated in Formula (4), or pharmaceutically acceptable slats thereof. R1 can be chosen from hydroxyl, benzyloxy, phenoxy, substituted phenoxy, or substituted benzyloxy. R2, R3, R4, R5 can be chosen from hydrogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, benzyloxyphenyl, substituted benzyloxyphenyl, nitro, fluorine, chlorine, bromine, or iodine. Also disclosed are a preparation method for and applications of said compound.
    Type: Application
    Filed: November 10, 2011
    Publication date: November 7, 2013
    Applicant: SHANGHAM TECH-WELL BIOPHARMACEUTICAL CO., LTD
    Inventors: Bingming He, Ming Li, Zhijun Tang, Xiaoming Ji
  • Patent number: 8575094
    Abstract: A method for the treatment or prophylaxis of a microbial infection of the lower intestine or colon in a subject is described, wherein the method comprises administration to the subject of a type-B lantibiotic, wherein the type-B lantibiotic may include compounds selected from the group consisting of mersacidin, actagardine, plantaricin, planosporicin, ruminococcin, antibiotic 10789, michiganin and haloduracin, and derivatives and variants thereof.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: November 5, 2013
    Assignee: Novacta Biosystems Limited
    Inventors: Sjoerd Nicolaas Wadman, Michael John Dawson, Jesus Cortes Bargallo
  • Publication number: 20130288965
    Abstract: The current invention relates to the use of a peptide comprising an amino acid sequence in the preparation of a medicament for the regeneration of tissue, preferably for the treatment of a wound. Further the invention relates to compositions comprising such peptides, and use of said peptides in both medical and nonmedical (cosmetic) applications.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 31, 2013
    Inventors: JOHANNES GERHARDUS MARIA BOLSCHER, ARIE VAN NIEUW AMERONGEN, ENGELMUNDUS CORNELIS IGNATIUS VEERMAN, MENNO JOHANNES OUDHOFF, WILLEM VAN'T HOF, KAMRAN NAZMI, PETRONELLA ADRIANA MARIA VAN DEN KEIJBUS
  • Patent number: 8569246
    Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.
    Type: Grant
    Filed: December 31, 2012
    Date of Patent: October 29, 2013
    Assignee: Synergy Pharamaceuticals Inc.
    Inventor: Kunwar Shailubhai